Science • Medicine
2021-03-23T16:00:02+00:00

Independent US board "concerned" AstraZeneca may have included outdated information from its Covid-19 vaccine trial

The National Institute of Allergy and Infectious Diseases (NIAID) has released a statement, saying that the Data and Safety Monitoring Board (DSMB), an independent group of experts that advises US National Institute of Dental and Craniofacial Research, was concerned "that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data."

"Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial,” the statement says. “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”

Pentributor:
Highly edible human, designer of all things digital, co-founder of Pendect, creative native, constant wa/onderer, morse code lady, full-time dog pillow.
Card reviewed by: @ericof